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OBJECTIVES: Alcoholic hepatitis (AH) develops in approximately 30% of chronic heavy drinkers. The immune system
of patients with AH is hyperactivated, yet ineffective against infectious diseases. Mucosal-associated
invariant T (MAIT) cells are innate-like lymphocytes that are highly enriched in liver, mucosa, and
peripheral blood and contribute to antimicrobial immunity. We aimed to determine whether MAIT cells
were dysregulated in heavy drinkers with and without AH and the effects of alcohol abstinence on
MAIT cell recovery.
METHODS: MR1 tetramers loaded with a potent MAIT cell ligand 5-(2-oxopropylideneamino)-6-d-
ribitylaminouracil were used inmultiparameter flow cytometry to analyze peripheral bloodMAIT cells in
59 healthy controls (HC), 56 patients with AH, and 45 heavy drinkers without overt liver disease (HDC)
at baseline and 6- and 12-month follow-ups. Multiplex immunoassays were used to quantify plasma
levels of cytokines related to MAIT cell activation. Kinetic Turbidimetric Limulus Amebocyte Lysate
Assay and ELISA were performed to measure circulating levels of 2 surrogate markers for bacterial
translocation (lipopolysaccharide and CD14), respectively.
RESULTS: At baseline, patients with AH had a significantly lower frequency of MAIT cells than HDC and HC. HDC
also had lessMAIT cells thanHC (median0.16% inAH, 0.56% inHDC, and 1.25% inHC). Further, the
residualMAIT cells in patients with AH expressed higher levels of activationmarkers (CD69, CD38, and
human leukocyte antigen [HLA]-DR), the effector molecule granzyme B, and the immune exhaustion
molecule PD-1. Plasma levels of lipopolysaccharide and CD14 and several cytokines related to
MAIT cell activation were elevated in patients with AH (interferon [IFN]-a, interleukin [IL]-7, IL-15, IL-
17, IL-18, IL-23, IFN-g, and tumor necrosis factora). DecreasedMAIT cell frequency and upregulated
CD38, CD69, and HLA-DR correlated negatively and positively, respectively, with aspartate
aminotransferase level.MAIT cell frequency negatively correlated with IL-18.HLA-DR andCD38 levels
correlated with several cytokines. At follow-ups, abstinent patients with AH had increased MAIT cell
frequency and decreased MAIT cell activation. However, MAIT cell frequency was not fully normalized
in patients with AH (median 0.31%).
DISCUSSION: We showed that HDC had a reduction of blood MAIT cells despite showing little evidence of immune
activation, whereas patients with AH had a severe depletion of blood MAIT cells and the residual cells
were highly activated. Alcohol abstinence partially reversed those abnormalities.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A52, http://links.lww.com/CTG/A53, and http://links.lww.com/CTG/A54
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INTRODUCTION
Excessive alcohol consumption causes hepatocellular injury
through direct cytotoxic eﬀects and oxidative stress mediated by
ethanol and its metabolites and induction of proinﬂammatory
cascades. Up to a third of long-term heavy drinkers develop
a spectrum of severe alcoholic liver disease (ALD), ranging from
alcoholic hepatitis (AH), ﬁbrosis/cirrhosis, to hepatocellular
carcinoma. Approximately 10%–35% of the heavy drinking
population develops AH, a severe and progressive acute-on-
chronic liver inﬂammation disease with signiﬁcantmorbidity and
mortality, for which there are limited treatment options (1–3).
AH is clinically characterized by hyperbilirubinemia, coagulop-
athy, elevation of liver enzyme levels, and features of the systemic
inﬂammatory response syndrome in heavy drinkers with a his-
tory of recent alcohol abuse. Although the exact trigger for de-
velopment of AH is still not well-understood, alcohol-induced
dysregulation of both innate and adaptive immune systems has
been implicated in the pathogenesis of AH (4–7).
Excessivedrinking leads todysbiosis of gutmicrobiome (8–10),
which contributes to alcohol-induced breakdown of gastrointes-
tinal (GI) tract barrier. Increased intestinal permeability results in
the translocation of microbes and microbial products from the GI
tract into blood, which reach the liver through the portal vein,
activating both innate and adaptive immune cells that have been
sensitized by alcohol and itsmetabolites (11,12). The liver-resident
macrophages, Kupﬀer cells, play a critical role in initiating and
driving liver inﬂammation in AH by releasing proinﬂammatory
eﬀectors including cytokines and chemokines upon recogni-
tion of pathogen-associated molecular patterns, such as lip-
opolysaccharides (LPS), anddanger-associatedmolecular patterns
released from injured hepatocytes. Cytokines and chemokines
secreted by Kupﬀer cells and other intrahepatic immune and
nonimmune cells promote recruitment of polymorphonuclear
neutrophils, monocytes, and T cells into the liver, leading to fur-
ther liver injury and inﬂammation (13,14). Patients with AH have
elevated circulating levels of a variety of proinﬂammatory factors,
such as IL-8, tumor necrosis factor (TNF)-a, interleukin (IL)-6,
monocyte chemoattractant protein (MCP)-1, and macrophage
inﬂammatory protein (MIP)3, which serves as a positive feedback
loop to further enhance hepatocellular damage, GI tract perme-
ability, and immune dysregulation. In addition, both the innate
and adaptive immune cells are functionally defective in patients
with AH (5,15). Innate immune cells including neutrophils and
monocytes exhibit defective antimicrobial responses including
impaired phagocytosis and oxidative burst in patients with AH
(16). T cells in patients with AH express high levels of activation
markers and immune inhibitory/exhaustion molecules, such as
PD-1 and TIM3 (3,16). Those primed T cells have defective IFN-g
production and are ineﬀective against pathogens, leading to an
increased susceptibility to infection in patients with AH (15–17).
Increasing evidence has suggested that mucosal-associated
invariant T (MAIT) cells, an innate-like T lymphocyte subset,
play a protective role in antimicrobial immunity (18,19).
MAIT cells express high levels of the C-type lectin receptor
CD161 and are predominantly CD8-positive with only a small
fraction of CD4-positive subset and some double negative (DN)
(CD82CD42) cells. The T-cell receptor (TCR) expressed by
MAIT cells is of limited diversity, consisting of a dominant in-
variant alpha chain (Va7.2-Ja33) and a restricted number of beta
chain (Vb2 orVb13) (20).MAIT cells are activated by vitaminB2
biosynthesis precursor derivatives produced by a range of path-
ogenic and commensal microbes in the context of the highly
evolutionarily conserved monomorphic MHC class-I-like mole-
cule MR1 on antigen-presenting cells (21,22). In addition,
MAIT cells express high levels of IL-18 receptor and can be ac-
tivated by a TCR-independent but cytokine-dependent pathway,
in which IL-18 synergizes with IL-12, IL-15, or IFN-a/b (23–26).
IL-23 can also stimulate MAIT cells (27). Thus, this cytokine-
dependent activation of MAIT cells broadens their role to viral
infections and inﬂammatory/autoimmune diseases even in the
absence of bacterial antigen recognition (19,28). Further, IL-7 and
IL-15 cytokines enhance TCR-mediated MAIT cell activation
(29–31). Upon activation, MAIT cells rapidly produce proin-
ﬂammatory cytokines TNF-a, IFN-g, and IL-17 and upregulate
cytotoxic molecules granzyme B and perforin that contribute to
inﬂammation and host defense.
MAIT cells are abundant in the mucosal tissues, such as the
intestine (2%–10% of T cells) and the lungs (1%–10% of T cells),
and the peripheral blood (0.1%–10% of T cells). Strikingly,
MAIT cells are highly enriched in the human liver, accounting for
10%–40%of hepatic T cells (32). This dominance ofMAIT cells in
the liver suggests that they could play a major role in host defense
and inﬂammation in various liver diseases, including ALD
(19,32–34). It has been demonstrated that the frequency of
MAIT cells in the blood and liver is signiﬁcantly reduced in
several chronic inﬂammatory and autoimmune liver diseases and
ALD (35,36). In addition, a recent comprehensive study has
revealed that CD81 MAIT cells are markedly depleted from the
blood of patients with severe AH and alcohol-related cirrhosis
(ARC), and the remaining MAIT cells have hyperactivated phe-
notype yet are functionally defective in cytokine and cytotoxic
responses (37). Furthermore, these MAIT cell alterations are not
reversed after a short-term alcohol abstinence of 2–5 days (37). As
it takes several weeks for GI tract barrier function to recover
(10,38), the eﬀect of long-term alcohol cessation on MAIT cell
recovery remains unknown.
Currently, it is not well-understood why alcohol abuse causes
AH in a subset of patients with excessive alcohol use and what
determines the severity of AH. Most studies have compared
patients with AH with healthy controls (HC) or patients with
ARC to try to understand the immunological diﬀerences un-
derlying the apparent individual susceptibility to AH. Here, we
conducted a study to characterize MAIT cells in a large cohort of
patients with AH, heavy drinkers without clinic evidence of liver
disease (HDC), andHC.We also correlatedMAIT cell phenotype
with patients’ clinical parameters and plasma levels of several
markers of bacterial translocation and cytokines related to
MAIT cell activation and function. Finally, we performed cross-
sectional and longitudinal analysis to determine the eﬀect of long-
term alcohol abstinence on reversing abnormalities in MAIT cell
frequency and phenotype. We found that alcohol cessation im-
proved but did not completely reverseMAIT cell abnormalities in
patients with AH.
METHODS
Study subjects
This study was approved by the Institutional Review Boards at
Indiana University School of Medicine, Mayo Clinic, and Vir-
ginia Commonwealth University. All participants provided
a written informed consent form before blood was drawn. The
study subjects (56 patients with AH and 45 HDC at baseline, 24
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Table 1. Comparison of characteristics of patients with AH and HDC in the TREAT study cohort
Variable
Day 0 (baseline) Day 180 Day 360
HC (n5 59) AH (n5 56) HDC (n5 45) P AH (n 5 24) HDC (n5 25) P AH (n5 15) HDC (n 5 22) P
Age at enrollment (yr) 41 6 14 456 10 436 10 ns 436 10 43 6 10 ns 46 6 11 46 6 10 ns
Gender (% male) 53 61 64 ns 63 64 ns 53 68 ns
Race (% white) 71 95 78 ns 95 80 ns 100 64 **
Total drinks in the last 30 d 2376 221 4126 409 * 4 6 12 26 6 61 ns 12 6 46 80 6 188 ns
Total drinking d in the last 30 d 226 10 256 7 ns 1 6 4 4 6 8 ns 2 6 8 10 6 14 ns
MELD score 256 7 76 2 *** 156 9 7 6 1 *** 12 6 6 7 6 1 ***
Creatinine (mg/dL) 0.9 6 0.2a 1 6 0.7 0.96 0.3 ns 1 6 0.8 1 6 0.2 ns 1 6 0.4 1 6 0.2 ns
Total bilirubin (mg/dL) 0.5 6 0.2a 18.1 6 12.8### 0.6 6 0.3 *** 3.6 6 4.1 0.4 6 0.2 *** 2.4 6 3.9 0.5 6 0.2 ***
AST (IU/L) 18 6 6a 1236 55### 266 9§§ *** 596 49 20 6 6 *** 42 6 29 30 6 30 **
ALT (IU/L) 14 6 7a 506 27### 256 10§§§ *** 356 22 17 6 8 *** 26 6 14 26 6 19 ns
Prothrombin time (INR) 1.9 6 0.5 16 0.1 *** 1.5 6 0.6 1 6 0.1 *** 1.3 6 0.5 1 6 0.1 ***
Data are represented asmean6 SD. Kruskal-Wallis test with Dunn’s correction for pairwise comparisons of continuous variables amongHC, patients with AH, andHDC at enrollment (day 0). Mann-Whitney test comparing patients
with AH vs HDC at 180-day and 360-day follow-up. Chi-square test for analysis of categorical variables.
AH, alcoholic hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HC, healthy controls; HDC, heavy drinking controls; INR, international normalized ratio; MELD, model for end-stage liver disease; ns, not
significant.
aData from 44 HC.
###P, 0.001 for comparison between patients with AH andHCat day 0; *P, 0.05; **P, 0.01; ***P, 0.001 for comparison between patients with AHandHDC; §§P, 0.01; §§§P, 0.001 for comparison betweenHDC andHC
at day 0.
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patients with AH and 25 HDC at 180-day follow-up, and 15
patients with AH and 22HDC at 360-day follow-up) were part of
the multicenter prospective Translational Research and Evolving
Alcoholic Hepatitis Treatment 001 study (TREAT 001,
NCT02172898). Demographic and clinical characterizations as
well as drinking patterns of the study subjects are shown in
Table 1. Detailed deﬁnitions of AH and HDC and the inclusion
and exclusion criteria were previously described (39). HDC were
individuals with a comparable history of alcohol consumption
but had no clinical evidence of liver disease (aspartate amino-
transferase [AST] # 50 U/L, alanine aminotransferase [ALT] #
50 U/L, and total bilirubin within normal limits) and were
matched for age, sex, and race. Individuals with liver diseases of
other etiologies and clinically overt and active infection were
excluded from this study.
Blood samples
Peripheral blood was collected in heparin-coated tubes (BD
Biosciences, Franklin Lakes, NJ) and separated into plasma and
peripheral blood mononuclear cells (PBMCs). Both plasma and
PBMCs were stored at 280 °C until use. PBMC and plasma
samples from 59 age-, sex-, and race-matched healthy volunteers
were included as HC.
Flow cytometry
PBMCs were subjected to cell surface staining and intracellular
staining to determine leukocyte frequency and phenotype. For cell
surface staining, PBMCs were incubated with ﬁxable viability dye
(ThermoFisher Scientiﬁc, Waltham, MA) to discriminate live and
dead cells, followed by staining with ﬂuorochrome-conjugated
antibodies against human CD3, CD4, CD8, CD161, CD38, CD56,
CD69, HLA-DR, gamma delta T (gd T) cells, invariant natural killer
T (iNKT) cells (all from BioLegend, San Diego, CA), and human
MR1 tetramers loaded with a potentMAIT cell ligand 5-OP-RU (5-
(2-oxopropylideneamino)-6-d-ribitylaminouracil). Appropriate
isotype controls were used at the same protein concentration as the
test antibodies for control staining, and human MR1 tetramers
loadedwith6-FP(6-formylpterin)wereusedas anegative control for
MAITcell staining.HumanMR1 tetramers loadedwith5-OP-RUor
6-FPwere produced by theNIHTetramerCore Facility as permitted
to be distributed by the University of Melbourne. Cells stained with
surface markers were ﬁxed and permeabilized with the Cytoﬁx/
Cytoperm reagents (BDBiosciences, San Jose, CA). For intracellular
staining, ﬁxed cells were permeabilized with the Cytoﬁx/Cytoperm
reagents (BD Biosciences), followed by staining with antibodies
against granzyme B (BioLegend) and active form of caspase 3 (BD
Biosciences). Cells were subsequently acquired using a BD
LSRFortessa ﬂow cytometer (BD Biosciences). Flow data were ana-
lyzed using FlowJo v10 software (Tree Star, San Carlos, CA).
Plasma endotoxin and soluble CD14
Plasma levels of the endotoxin LPS from Gram-negative bacteria
and soluble CD14 (sCD14) were used as surrogate markers for
bacterial translocation from gut to circulation. LPS amounts were
determined using the PYROGENT-5000 Kinetic Turbidimetric
Limulus Amebocyte Lysate Assay (Lonza, Walkersville, MD).
Plasma samples were diluted 5-folds in endotoxin-free water and
heated at 70 °C for 20minutes before being subjected to the assay.
Plasma sCD14 levels were quantiﬁed using the Human CD14
Quantikine kit (R&D Systems, Minneapolis, MN).
Multiplex immunoassays
The Cytokine/Chemokine/Growth Factor 45-Plex Human Pro-
cartaPlex Panel 1 (ThermoFisher Scientiﬁc) was used to simul-
taneously measure plasma concentrations of 45 proteins (BDNF,
Eotaxin/CCL11, EGF, FGF-2, GM-CSF, GROa/CXCL1, HGF,
NGF-b, LIF, IFN-a, IFN-g, IL-1b, IL-1a, IL-1RA, IL-2, IL-4, IL-
5, IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12 p70, IL-13, IL-15, IL-
17A, IL-18, IL-21, IL-22, IL-23, IL-27, IL-31, IP-10/CXCL10,
MCP-1/CCL2, MIP-1a/CCL3, MIP-1b/CCL4, regulated upon
activation normal T cell expressed and secreted [RANTES]/
CCL5, stromal cell‐derived factor [SDF]-1a/CXCL12, TNF-a,
TNF-b/LTA, platelet-derived growth factor [PDGF]-BB,
placenta Growth Factor [PLGF], stem‐cell factor [SCF],
vascular endothelial growth factor [VEGF]-A, and VEGF-D).
Multiplex assay was conducted as previously described (17). The
concentrations of cytokines/chemokines were calculated using
the Bio-PlexManager v6.1 software (Bio-Rad, Hercules, CA). For
statistical analyses, values below the detection limit of the assay
were replaced with the minimal detectable concentrations for
each analyte as provided by the manufacturer.
Statistical analysis
Diﬀerences in cross-sectional analysis for continuous variables
between 2 groups were calculated using Mann-Whitney test and
Kruskal-Wallis test with Dunn’s corrections for comparisons
among 3 groups. Chi-square test was used for comparison be-
tween groups for categorical variables. The linear relationship
between 2 variables was analyzed using the Spearman correlation
test. Diﬀerences in longitudinal analysis were calculated using
Friedman rank sum test with Dunn’s corrections. P , 0.05 was
considered statistically signiﬁcant.
RESULTS
Characteristics of the study cohort
Table 1 summarizes the demographic and clinical characteristics of
56patientswithAH, 45HDC, and59HCat enrollment; 24patients
with AH and 25 HDC at 6-month follow-up; and 15 patients with
AHand22HDCat 12-month follow-up.Therewere nodiﬀerences
in age, gender, and race distributions and creatinine levels among
the 3 groups at baseline and between patientswithAHandHDC at
follow-up. Although the amounts of baseline total bilirubin were
similar between HDC and HC, both AST and ALT levels were
modestly and signiﬁcantly higher in HDC than HC. The baseline
model for end-stage liver disease (MELD) score or liver bio-
chemistries (AST, ALT, and total bilirubin) were highly elevated in
patients withAHas compared toHDCandHC. Prothrombin time
was also signiﬁcantly longer for the patients with AH than HDC.
Interestingly, theHDC had signiﬁcantlymore drinks than patients
with AH before the enrollment. At the follow-up, both patients
with AH and HDC drank much less and the liver biochemistries
greatly improved in AH patients and remained unchanged for HDC.
However, patientswithAHstill hada signiﬁcantlyhigherMELDscore
due to elevated levels of liver biochemistries and prolonged pro-
thrombin time. The complete abstinence rate was 79% and 87% for
patients with AH and 68% and 59% for HDC at 6 and 12 months,
respectively. TheMELD score, total bilirubin, AST, and prothrombin
time remained higher in abstinent patients with AH at 6 and 12
months compared to abstinent HDC (Supplementary Table 1,
Supplementary Digital Content 3, http://links.lww.com/CTG/A54).
However, ALT levels were similar between patients with AH and
HDC at 12-month follow-up (Supplementary Table 1, Supplementary
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Digital Content 3, http://links.lww.com/CTG/A54). Fifteen of the 56
patients with AH died within 6 months after recruitment.
CirculatingMAIT cells were severely depleted inpatientswithAH
To analyze the impact of chronic heavy drinking on peripheral
MAIT cells, we ﬁrst analyzed the frequency of MAIT cells in pe-
ripheral blood in patients with AH and HDC as compared to HC.
MAIT cells were identiﬁed as CD31 lymphocytes that express high
level of CD161 and are stained by the 5-OP-RU-loaded MR1 tet-
ramers (40). The staining speciﬁcity was veriﬁed by the negative
control MR1-6-FP tetramers. At baseline, MAIT cells were signiﬁ-
cantly depleted in patients with AH as compared to HC and HDC
(Figure 1a,b). HDC also had signiﬁcantly less MAIT cells than HC
(Figure 1a,b). Speciﬁcally, MAIT cells accounted for a median of
0.16%(range: 0.03%–1.9%; interquartile range [IQR]: 0.09%–0.34%),
0.56% (range: 0.03%–7.22%; IQR: 0.23%–1.41%), and 1.25% (range:
0.05%–5.17%; IQR: 0.63%–2.32%)T cells in patientswithAH,HDC,
andHC, respectively. This decrease of peripheralMAIT cells was not
due to enhanced cell death, because there was no increase in active
form of caspase 3, a marker for apoptosis (Figure 1c) or down-
regulation of CD161 for MAIT cells in patients with AH or HDC
(Figure 1a). As a comparison, the frequency of CD161-expressing
non-MAIT T cells, which contain highly proinﬂammatory CD41
and CD81 cells (41), was not decreased, but signiﬁcantly increased
in patients with AH compared to HC and HDC (Figure S1A, Sup-
plementary Digital Content 1, http://links.lww.com/CTG/A52).
Figure 1.Baseline peripheral bloodMAITcells were severely depleted in patients with AH. (a) Representative flow plots showingMAITcell frequency in HC,
patients with AH, and HDC at baseline. MAITcells were CD161hi and stained by MR1 (major histocompatibility complex, class I-related) tetramers loaded
with 5-OP-RU. MR1 tetramers loaded with 6-FP was used as a negative staining control. (b, c) Pooled data of MR1 tetramer-positive cells showing
the frequency of MAITcells (b) and active caspase 31MAITcells (c) at baseline (D0) and 180-day (D180) and 360-day (D360) follow-up. Kruskal-
Wallis test with Dunn’s corrections was performed to compare expression levels among HC, AH, and HDC groups at D0 and D360. Mann-Whitney
test was used for comparisons at D180 or D360 (*P, 0.05, **P, 0.01, ***P, 0.001). Horizontal lines represent the median. 5-OP-RU, 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil; 6-FP, 6-formylpterin; AH, patients with alcoholic hepatitis; HC, healthy controls; HDC, heavy drinking controls;
MAIT, mucosal-associated invariant T cell; ns: not significant.
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In homeostasis, the majority of MAIT cells are CD8-positive with
a small percentagebeingCD4-positive, orDNforCD4andCD8(42).
There was a signiﬁcant decrease of CD8-expressing MAIT cells, and
a corresponding increase in CD4-expressing MAIT cells in patients
with AH as compared to HDC and HC (Figure S1B/S1C, Supple-
mentary Digital Content 1, http://links.lww.com/CTG/A52). The
frequencies of DN cells were similar among patients with AH, HDC,
and HC (Figure S1D, Supplementary Digital Content 1, http://
links.lww.com/CTG/A52). There were no signiﬁcant diﬀerences
in the frequency of several other types of innate T cells, in-
cluding NKT, iNKT, and gd T cells, among patients with AH,
HDC, and HC (Figure S2, Supplementary Digital Content 2,
http://links.lww.com/CTG/A53).
Patients with AH tended to have lower frequency ofMAIT cells
than HDC at 6-month follow-up (P 5 0.08) and at 12-month
follow-up (P 5 0.10) (Figure 1b). Furthermore, frequency of
MAIT cells at 12-month follow-up in both patients with AH
(median: of 0.31%; range: 0.04%–1.45%; IQR: 0.17%–0.46%) and
Figure 2. Peripheral blood MAITcells were highly activated in patients with AH. Scatter plots showing expression of activation markers (CD69, CD38, and
HLA-DR [DR]), granzymeB (GRB), and the immune inhibitor PD-1 inMAITcells fromHC, patients with AH, andHDC at baseline (D0) and 180-day (D180)
and 360-day (D360) follow-up. Kruskal-Wallis test with Dunn’s correctionswas performed to compare expression levels amongHC, AH, andHDCgroups at
D0. Mann-Whitney test was used for comparisons at D180 or D360 (*P, 0.05, **P, 0.01, ***P, 0.001). Horizontal lines represent the median. AH,
patients with alcoholic hepatitis; HC, healthy controls; HDC, heavy drinking controls; MAIT, mucosal-associated invariant T cell; ns: not significant.
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Table 2. Comparison of levels of inflammatory factors related to MAIT cell activation
Variable
Day 0 (baseline) Day 180 Day 360
HC (n5 43–47) AH (n5 51–55) HDC (n5 40–43) AH (n5 18–21) HDC (n 5 19–23) AH (n 5 13–14) HDC (n5 15–17)
Stimulation related factors
LPS (EU/mL) 0.01 6 0.01### 2.78 6 10.34*** 0.02 6 0.04 38.83 6 119.3 0.02 6 0.02 0.11 6 0.33 0.04 6 0.06
sCD14 (ng/mL) 1,391 6 530### 2,489 6 1,110*** 1,619 6 462 1,435 6 394 1,269 6 256 1,697 6 505 1,405 6 328
IFN-a (pg/mL) 1.1 6 1.6 3.4 6 4.7** 1.36 3 3.4 6 5.4 3 6 6.2 3.66 5.7 2.76 5.8
IL-7 (pg/mL) 0.5 6 1## 2.1 6 3.3** 0.56 1.3 1.5 6 1.8** 0.4 6 0.4 0.66 0.4 0.66 0.8
IL-12 (pg/mL) 1.3 6 0.5### 2.1 6 1.8 1.56 0.4 1.8 6 0.7** 1.2 6 0.6 1.46 0.6 1.16 0.6
IL-15 (pg/mL) 18.2 6 37 41.8 6 73.2* 22.4 6 59.4 65.2 6 116.5* 59 6 144.2 736 144.2 55.9 6 149.3
IL-18 (pg/mL) 15.4 6 15.9### 87.7 6 91*** 26.5 6 37.7 66.8 6 75.8** 21 6 17.9 54.7 6 49.3** 24.3 6 12.9
IL-23 (pg/mL) 35.6 6 35### 115.7 6 204*** 25.3 6 14.9 65.8 6 42.7*** 21.2 6 23.8 566 47.4* 28.5 6 25.7
Effectors
IFN-g (pg/mL) 4.9 6 5.1### 32.1 6 33.8*** 9.2 6 10.6 23.2 6 21.3* 9.1 6 12.2 19.2 6 14.1* 10.3 6 12.5
IL-17 (pg/mL) 0.8 6 1.8## 15.3 6 32** 0.76 1.6 2.3 6 2.3* 1.5 6 3.3 1.56 2 1.56 3.8
TNF-a (pg/mL) 6.5 6 6.1### 14.8 6 18.1*** 8.3 6 10.2 20.3 6 16.9* 11.6 6 11.5 14.6 6 14.5 9.9 6 11.9
Data are represented asmean6SD. Kruskal-Wallis test withDunn’s correction for pairwise comparisons amongHC, patients with AH, andHDCat baseline (day 0).Mann-Whitney test comparing patients with AHvsHDCat 180-day
and 360-day follow-up.
AH, alcoholic hepatitis; HC, healthy controls; HDC, heavy drinking controls; IFN, interferon; IL, interleukin; LPS, lipopolysaccharides; MAIT, mucosal-associated invariant Tcell; sCD14, soluble CD14; TNF, tumor necrosis factor.
##p , 0.01; ###p , 0.001 for comparison between patients with AH and HC at day 0; *P , 0.05; **P, 0.01; ***P, 0.001 for comparison between AH patients and HDC.
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HDC (median: 0.61%; range: 0.03%–4.05%; IQR: 0.17%–1.37%)
was still signiﬁcantly lower than that in HC (Figure 1b). However,
the percentage ofCD81, CD41,DN, andcaspase31MAITcells and
CD1611 non-MAIT cells was not diﬀerent between the AH and
HDC groups at the follow-up. Thus, at baseline, MAIT cells were
selectively depleted in patients with AH, and the remaining
MAIT cells had alteredCD4 andCD8T cell coreceptor expression.
There was a partial, but not complete, recovery of MAIT cells at
follow-up in patients with AH.
Residual MAIT cells in patients with AH expressed higher levels
of activation markers
We have recently reported that the CD4 and CD8 T cells from
patients with AH are highly dysregulated, expressing higher ac-
tivationmarkers such as CD69 and CD38 than T cells fromHDC
(17). Here, we examined whetherMAIT cells in patients with AH
were also hyperactivated. Compared with HDC and HC, signif-
icantly higher percentages of MAIT cells from patients with AH
expressed CD69 and CD38, whereas those markers were not signif-
icantly elevated inMAITcells fromHDCrelative toHC(Figure 2a,b).
MAIT cells from patients with AH also expressed signiﬁcantly more
HLA-DR (another T-cell activation marker) than HC, whereas the
frequencies of CD38 and HLA-DR double-positive cells (often used
as an indicator of T-cell activation in chronic inﬂammation)were not
diﬀerent among the heavy drinkers andHC (Figure 2c,d). Consistent
with expressing higher levels of surface activation markers,
MAIT cells from patients with AH also contained signiﬁcantly more
granzyme B thanHC, but not more thanHDC (Figure 2e). T cells in
patients withAH express higher levels of several immune checkpoint
inhibitory or exhaustion molecules such as TIM3 and PD-1 (16). As
shown in Figure 2f, a higher percentage of MAIT cells from patients
with AH expressed PD-1 as compared to HC, and the diﬀerence
between the AH and HDC groups was not signiﬁcant.
Further cross-sectional analyses of follow-up samples
showed that only CD38 expression on MAIT cells was still
higher in patients with AH than HDC at 6-month follow-up,
and the expression of all those markers on MAIT cells was not
signiﬁcantly diﬀerent between the AH and HDC groups
(Figure 2a–f). Taken together, our results indicated that blood
MAIT cells in patients with AH were highly activated
and exhausted. These cellular abnormalities were reversed at
12-month follow-up, which corresponded with reduced alco-
hol consumption.
Soluble factors related to MAIT cell activation were elevated in
patients with AH
MAIT cells recognize and are activated by MR1 receptors com-
plexed with vitamin B2 biosynthesis precursor derivatives from
Table 3. Correlations of MAIT cell markers with clinical and inflammatory factors in patients with AH
Variable % MAIT % CD691 % CD381 % HLA-DR1 % GRB1 % PD-11
Clinical parameters
MELD
Creatinine 0.3*
Total bilirubin
AST 20.36** 0.35** 0.28* 0.3*
ALT
INR
Stimulation-related factors
LPS
sCD14 0.38** 0.48***
IFN-a 0.46***
IL-7 0.35* 0.4** 0.33*
IL-12 0.4**
IL-15 0.51*** 0.3*
IL-18 20.36** 0.37** 0.29*
IL-23 0.31*
Effectors
IFN-g 0.41** 0.33*
IL-17 0.36*
TNF-a 0.54*** 0.56***
The numbers represent Spearman’s coefficients. Negative numbers represent negative correlations.
AH, alcoholic hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GRB, granzyme B; IFN, interferon; IL, interleukin; INR, international normalized
ratio for prothrombin time; LPS, lipopolysaccharides;MELD,model for end-stage liver disease;MAIT,mucosal-associated invariant Tcell; sCD14, solubleCD14; TNF, tumor
necrosis factor.
*P, 0.05; **P, 0.01; ***P, 0.001.
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a wide range of Gram-negative and Gram-positive bacteria. In
AH, impaired integrity of the GI tract leads to translocation of
bacterial components to circulation. We therefore measured cir-
culatory levels of LPS derived from Gram-negative bacteria and
sCD14, a receptor for LPS that is secretedbyactivatedmacrophages
and monocytes, as a marker for bacterial translocation. As shown
in Table 2, the baseline LPS and sCD14 levels were elevated in
patients withAH in comparison toHDCandHC,whereas levels of
those factors were not signiﬁcantly upregulated inHDC compared
toHC.At 6- and 12-month follow-ups, the amounts of both factors
were similar between the AH and HDC groups.
MAIT cells can also be activated in a TCR-independent
manner by cytokines, such as IL-18, IL-12, IL-15, IFN-a, IL-23,
IL-7, to produce eﬀector cytokines (IFN-g, IL-17, and TNF-a),
which might further enhance expression of MAIT cell activation
markers. As shown in Table 2, patients with AH had signiﬁcantly
higher baseline plasma levels of IL-7, IL-18, IL-23, IL-17, IFN-g,
and TNF-a compared to the HDC and HC groups. Additionally,
the patients with AH had elevated baseline levels of IFN-a. In
contrast, levels of these cytokines were not signiﬁcantly diﬀerent
between HDC and HC. At 6-month and 12-month follow-up,
cytokine levels greatly decreased from the baseline values in
patients with AHwhile remaining unchanged in HDC. However,
at 6-month follow-up, all upregulated cytokines except IFN-a
remained signiﬁcantly higher in patients with AH than in HDC.
At 12-month follow-up, IL-18, IL-23, and IFN-g were still ele-
vated in the AH group. Taken together, our data indicated that
patients with AH had a higher circulatory level of factors as-
sociated with MAIT cells activation, which could contribute to
the hyperactivated status of MAIT cells at baseline. Reduced
cytokine production in patients with AH at follow-up was
reﬂected by partial recovery of MAIT cell frequency and
phenotype.
Association of MAIT cell frequency and phenotype with clinical
profiles and cytokine levels in patients with AH
To explorewhetherMAIT cellsmight be related to pathogenesis of
AH, we determined whether MAIT cell frequency and the activa-
tionmarkers correlatedwith disease severity representedbyclinical
scores (MELD score) and biochemical measurements (creatinine,
total bilirubin, AST, ALT) and prothrombin time in patients with
AH at baseline. AlthoughMAIT cell frequency and phenotype did
not correlate with the MELD score, the frequencies of MAIT cells
and MAIT cell activation markers CD69, CD38, and HLA-DR
correlated negatively and positively with level of the liver enzyme
AST, respectively, suggesting dysregulated MAIT cells might be
Figure3.ComparisonofMAITcell activationmarkers in abstinent subjects at 6-month and12-month follow-up. (a–c) Scatter plots showing the frequency of
MAITcells (a) and expression of activationmarkers CD38 (b), CD69 (c) at 180-day (D180) and 360-day (D360) follow-up in abstinent patients with AH and
HDC. (d). Scatter plot showing the frequency of MAIT cells in HC and 12-month follow-up samples of patients with AH and HDC. Mann-Whitney test
comparing patients with AH vs HDC at D180 and D360. Kruskal-Wallis test with Dunn’s corrections comparing expression levels among HC, AH, and HDC
groups (*P, 0.05, ***P, 0.001). Horizontal lines represent themedian. AH, patients with alcoholic hepatitis; HC, healthy controls; HDC, heavy drinking
controls; MAIT, mucosal-associated invariant T cell; ns: not significant.
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involved in liver damage. The percentage of PD-1-positive
MAIT cells correlated with the creatinine level (Table 3).
Next, we analyzed the correlations between MAIT cell phe-
notype and factors that are linked to MAIT cell activation. The
signiﬁcant correlations were listed in Table 3. Circulatory levels
of LPS did not correlate with MAIT frequency or activation
phenotype, whereas sCD14 level correlated with percentages of
CD691 and granzyme B1 MAIT cells. IL-18 was negatively as-
sociated with MAIT frequency and positively with CD381 (%)
and HLA-DR1 (%) MAIT cells. Other MAIT-stimulatory
cytokines (IL-7, IL-12, IL-15, and IL-23) also correlated with
CD381 (%) and HLA-DR1 (%) MAIT cells. Eﬀector cytokines
IL-17, IFN-g, and TNF-a also showed signiﬁcant correlations
with the frequency ofMAIT activationmarkers CD38 andHLA-
DR. Interestingly, the frequency of PD-11 MAIT cells in the
patients with AH inversely correlated with the percentage of
MAIT cells (r 5 0.41, P 5 0.003) as well as CD81 MAIT cells
(r5 0.35, P5 0.01). These results suggested that stimulation by
bacterial products and multiple cytokines could contribute to
MAIT cell hyperactivation and that immune exhaustion might
play a role in MAIT cell depletion.
Loss of MAIT cells was not fully reversed in patients with AH by
alcohol abstinence
To determine whether the partial recovery of MAIT abnor-
malities at follow-up was linked to alcohol abstinence in
patients with AH, we performed cross-sectional analysis on
follow-up samples between abstinent patients with AH and
HDC. As shown in Figure 3a,b, the frequencies of MAIT cells
and CD381MAIT cells were still signiﬁcantly lower and higher,
respectively, in the AH group at 6-month follow-up. Other
MAIT cell activation markers, including CD69, HLA-DR, and
Figure 4. Longitudinal analysis of dysregulated immunological factors in abstinent subjects. Longitudinal analysis of the effects of alcohol abstinence on
expression levels of MAITcell markers in patients with AH (a) and HDC (b). Friedman rank sum test with Dunn’s correction for comparing surface marker
expression at day 0 (D0)with 180-day (D180) follow-upor 360-day (D360) follow-up (n56–7). *P,0.05, **P,0.01. AH, alcoholic hepatitis;HDC, heavy
drinking controls; MAIT, mucosal-associated invariant T cell; ns: not significant.
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granzyme B level, were similar between the 2 groups (Figure 3c
and data not shown). No signiﬁcant diﬀerences in those
MAIT cell markers were detected at 12-month follow-up be-
tween the AH and HDC groups (Figure 3a–c). However,
patients with AH at the end of the study still had signiﬁcant
lower percentage of MAIT cells (median: 0.31%; range:
0.04%–1.45%; IQR: 0.14%–0.61%) than HC (median: 1.25%;
range: 0.05%–5.17%; IQR: 0.63%–2.32%), whereas MAIT cell
frequency in HDC (median: 0.63%; range: 0.03%–4.05%; IQR:
0.17%–1.26%) was lower but not signiﬁcantly diﬀerent from
that in HC (Figure 3d). In addition, the frequency of CD381
MAIT cells from abstinent patients with AH at 12-month
follow-up remained signiﬁcantly higher (median: 12.4%; range:
4.6%–52%; IQR: 8.5%–24.6%) than HC (median: 7.7%; range:
0%–37.5%; IQR: 4.2%–14.2%) (P 5 0.04).
Next, we performed longitudinal analysis of samples from
patients with AH and HDC who were completely abstinent at
follow-up.As shown in Figure 4a,MAIT cell frequency in patients
with AH was signiﬁcantly increased at 12-month but not
6-month follow-up; MAIT cells from abstinent patients with AH
had signiﬁcant reductions in CD69 and CD38 expression at
6-month follow-up and in CD38 expression at 12-month
(Figure 4a). In contrast, frequencies of MAIT cells and those
activation markers in abstinent HDC did not have signiﬁcant
changes throughout the study (Figure 4b). Taken together, our
data indicated that the dysregulated MAIT cell frequency and
MAIT activation markers in patients with AH recovered greatly,
but not completely, with alcohol cessation.
DISCUSSION
In the present study, we performed cross-sectional and longitu-
dinal analysis to compare frequency, phenotype, and function of
peripheral blood MAIT cells from a large cohort of patients with
AH,matched heavy drinkers, andHC (Table 1). The design of our
study allowed us to identify changes in MAIT cells related to
heavy drinking alone, during AH developments, and immune
system recovery following alcohol abstinence. We demonstrated
that patients with AH had a severe reduction of MAIT cells and
the residual MAIT cells exhibited a highly activated and
exhausted phenotype (Figures 1 and 2). On the other hand, HDC
only had a slight decrease in MAIT cell frequency and the
remaining MAIT cells did not exhibit signiﬁcant upregulation of
activation markers compared to HC. Baseline plasma levels of
markers of bacterial translocation to circulation (LPS and sCD14)
and several cytokines linked toMAIT cell activation (IFN-a, IL-7,
IL-12, IL-15, IL-18, IL-23, IFN-g, IL-17, and TNF-a) were highly
elevated in patients with AH (Table 2). Baseline MAIT cell fre-
quency and levels of MAIT activation markers CD69, CD38, and
HLA-DR correlated negatively and positively with AST in
patients with AH, respectively. MAIT cell frequency was also
negatively associated with IL-18, whereas up-regulated CD38 and
HLA-DR showed positive correlations with many of the cyto-
kines implicated in MAIT cell activation (Table 3). Analysis of
follow-up and longitudinal samples indicated MAIT cell abnor-
malities in patients with AH drastically improved but were not
completely reversed with alcohol cessation (Figures 3 and 4),
which was reﬂected by changes in their clinical characteristics.
Figure 5.Model ofMAITcell activation and depletion in patients with AH. Chronic heavy drinking induces dysbiosis of gutmicrobiome and breakdown of GI
tract barrier, which leads to translocation of gut bacteria and their products to the portal and systemic circulation in patients with AH. Bacterial products,
such as LPS, activate APC and other cells to releaseMAITcell-activating cytokines, including IL-18, IL-7, IL-15, and IL-23, and IFN-a. In addition, bacterial-
derived vitamin B2 metabolites presented by the major histocompatibility complex class I-related protein 1 (MR1) on APC activate MAITcells through the
invariant Va7.2-Ja33 T-cell receptor. Both the cytokine- and antigen-dependent signaling pathways of MAITcell activation contribute to upregulation of T-
cell activation markers (CD69, CD38, and HLA-DR), the T-cell exhaustion marker PD-1, and production of cytotoxic effector proteins (granzyme B and
perforin), and effector cytokines (IFN-g, IL-17, and TNF-a, which can serve as a positive feedback to further activateMAITcells). These hyperactivated and
exhausted MAIT cells are prone to activation-induced cell death, leading to depletion of hepatic and circulating MAIT cells and impaired antimicrobial
cytokine and cytotoxic responses for the residual MAITcells in patients with AH. AH, alcoholic hepatitis; APC, antigen-presenting cells; GI, gastrointestinal;
LPS, lipopolysaccharides; MAIT, mucosal-associated invariant T cell; TNF, tumor necrosis factor.
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Peripheral blood MAIT cells were markedly depleted in
patients with AH at enrollment as quantiﬁed by MR1-5-OP-RU
tetramer staining. This result conﬁrmed a previous ﬁnding that
blood MAIT cells are profoundly reduced in patients with severe
AH using CD161hiTCR-Va7.21 phenotyping to identify
MAIT cells (37). On the other hand, we did not ﬁnd major
changes in several other innate T-cell populations, such as NKT,
iNKT, and gd T cells, indicating that MAIT cells were speciﬁcally
depleted in AH. CD81 MAIT cells have been identiﬁed as the
dominant subset of MAIT cells. We and others have shown that
patients with AH have reduced frequency of total CD8 T cells in
circulation (5,17,19). In line with this general reduction of CD8
T cells in peripheral blood, we found that the frequency of CD81
MAIT cells was reduced with a corresponding increase in CD41
MAIT cells. Similar decrease in CD81MAIT cells and increase in
CD41 MAIT cells has been observed in several chronic liver
diseases, including ALD (35). In addition to overt cell exhaustion,
the loss of peripheral MAIT cells could be partly due to re-
distribution to the liver, although the existing data are contra-
dictory. One study has reported that CD161hiTCR-Va7.21
MAIT cells dramatically depleted in the blood, but the TCR-
Va7.21 cells (also include non-MAIT cells) were preserved in the
liver of patients with ARC (37). However, 2 other studies have
demonstrated that frequency ofCD161hiTCR-Va7.21MAITcells
are drastically reduced in both the blood and liver of patients with
end-stage ALD (35,43). Thus, further study with MR1 tetramers
to quantify MAIT cells in liver biopsies from patients with AH is
required to assesswhether bloodMAITcell depletion results from
MAIT cell recruitment into the liver or dysregulation of cell ho-
meostasis and survival.
MAIT cell depletion from the periphery, which is a common
occurrence in many infectious and inﬂammatory diseases, is
concurrent with upregulation of activation and exhaustion
markers (19,32,34). Hyperactivation often leads to activation-
induced cell death by apoptosis. Human MAIT cells are known
to have a proapoptotic phenotype in response to cell activation
(44). MAIT cells in this large cohort of patients with AH
expressed high levels of activation markers CD69, CD38,
HLA-DR, and the immune inhibitory/exhaustionmarker PD-1.
This is in line with ﬁndings showing that hyper-activated
MAIT cells in other diseases also express higher levels of in-
hibitory molecules PD-1 and TIM3 (19). However, a recent study
found no increase in expression levels of 3 immune checkpoint
inhibitors (PD-1,TIM3, andLAG3) in 9patientswithAHandARC
(37). In our study, we did not observe an increase in apoptotic
MAIT cells or non-MAIT T cells in patients with AH orHDC. It is
possible that apoptotic MAIT cells were rapidly cleared from the
circulation before sample collection or the cell death was in-
dependent of apoptosis.
In TCR-dependent activation, MAIT cells are activated by
MR-1 complexed with bacterial-derived vitamin B2 metabolites.
In AH, bacterial components and metabolites are released from
gut to circulation due to increased intestinal permeability (11,45).
We used LPS and sCD14 as surrogate markers for gut bacterial
translocation. Both markers were signiﬁcantly higher in patients
with AH than HDC and HC, which is consistent with the results
recently reported (9). Interestingly, fecal extracts containing gut
bacteria and bacterial antigens and metabolites (FEB) from
patients with severe AH and ARC, but not FEB from healthy
donors or ﬁxed laboratory strain of Escherichia coli, can induce
depletion and dysfunction of MAIT cells from PBMCs of healthy
donors (37). Although the underlying mechanism for this ob-
servation is unknown, dysbiosis of gut microbiome likely plays
a role. Recently, dysbiosis of the circulating microbiome in
patients with AH as well as in HDC has been shown as compared
to nondrinking controls (9). The relationship between dysbiosis
of gut and blood microbiome and MAIT cell dysregulation
requires further investigation.
Of the severalMAIT cell activation-related cytokines thatwere
upregulated in patients with AH, we found that multiple in-
ﬂammatory cytokines correlated with expression of the T-cell
activation markers CD38 and HLA-DR, which likely reﬂected
hyperinﬂammation in AH. Interestingly, we found that IL-18
level negatively correlated to MAIT frequency, suggesting that
IL-18 likely plays a role in MAIT cell depletion in patients with
AH. Currently, the relative contribution of TCR- and cytokine-
dependent pathways to MAIT cell alterations in AH is unknown.
Ex vivo studies showed that neither ALD plasma, which con-
tained higher levels of bacterial products and inﬂammatory
cytokines, nor alcohol treatment could induce MAIT cell de-
pletion from PBMCs obtained from healthy donors (37).We also
conﬁrmed that plasma from neither patients with AH nor HDC
could induce MAIT cell depletion from PBMCs of healthy
donors. Based on our results and published studies (35,37), we
propose that both antigen-dependent and cytokine-dependent
pathways play a role in driving MAIT cell hyperactivation and
depletion in patients with AH (Figure 5). Future study on the
potential role of alcohol or alcohol metabolites, bacterial metab-
olites, and inﬂammatory cytokines in MAIT cell depletion in
patients with AH is warranted.
HDC in our study were heavy drinkers without obvious signs
of clinical liver disease, although their AST and ALT levels were
slightly higher than HC. Our research groups have shown that
those subjects have higher serum levels of LPS and markers of
monocyte/macrophage activation (sCD14 and sCD163) com-
pared to nonexcessive drinkers in terms of bacterial translocation
(38). We showed here that HDC had a signiﬁcant decrease of
MAIT cells in the peripheral blood compared to HC. HDC had
slightly increased levels of the bacterial translocation marker
sCD14 and MAIT activation-associated cytokines IL-18 and
IL-12. This increase was signiﬁcant when 2-group comparison
between HDC and HC was performed. However, this diﬀerence
did not reach signiﬁcance due to lower statistical power for
3-group comparison (HC, AH, and HDC). Our study indicates
that chronic excessive drinking leads to slight immune abnor-
malities in HDC (17). Interestingly, MAIT cell frequency did not
diﬀer between HDC who stopped drinking and those who con-
tinued drinking at 12-month follow-up (data not shown). This
MAIT cell stability is also reﬂected by the nonprogression of
clinical disease severity. We have recently reported that the cir-
culating microbiome in HDC is also altered compared to non-
drinking controls (9), which might contribute to this MAIT cell
abnormality in HDC.
Complete alcohol abstinence is the key to immune system
recovery from AH, but it does not lead to full recovery in all
patients (46). Consistent with this, clinical scores and liver
function in our abstinent patients with AH greatly improved
but were still abnormal during the follow-up (Supplementary
Table 1, Supplementary Digital Content 3, http://links.lww.
com/CTG/A54).We have recently reported that levels of several
proinﬂammatory cytokines, such as TNF-a and IL-8, are still
elevated in insentient patients with AH than HDC at the end of
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12-month follow-up (17). Here, we found levels of 2 MAIT cell-
activating cytokines IL-18 and IL-23 remained higher in patients
withAHpatients after alcoholwithdrawal.Consistentwithapossible
role of IL-18 in depletion of peripheral bloodMAIT cells, MAIT cell
frequency in abstinent patientswithAHdidnot reach levels found in
healthy donors. This pattern ofMAIT cell recovery is reminiscent of
previous studies showing that severe depletion and functional im-
pairment of MAIT cells in the periphery of patients with HIV and
chronic HCV are not recovered after successful treatment with
antiretroviral therapies and direct-acting antivirals, respectively
(33,47,48). We previously showed that alcohol abstinence restored
abnormalities in CD4 and CD8 T cells, B cells, and monocytes,
suggesting alcohol might have a longer-lasting impact onMAIT cell
compartment. It is possible that MAIT cells have a low proliferation
rate (49), and a longer abstinence might be required for a full re-
covery of MAIT cells. MAIT cells might also be more sensitive to
bacterial products/cytokines, as ARC had defect in MAIT cells, but
not in adaptive T cells (16,37).
In conclusion, we found that HDC had a reduction of
MAIT cells despite showing little evidence of immune activa-
tion, whereas patients with AH had a severe depletion of
MAIT cells and the residual cells had highly dysregulated ex-
pression of multiple T-cell activation markers in the back-
ground of a higher level of bacterial translocation and immune
activation. MAIT cell dysfunction might be a contributing
factor to the weakened immunity against microbial infection in
patients with AH. Complete abstinence from alcohol con-
sumption greatly but not completely reversed MAIT abnor-
malities. Current medical therapies for AH are limited. Thus,
development of therapies to target dysregulated immune sys-
tems, includingMAIT cells, may represent a promising strategy
for restoring immune homeostasis and host defense against
infections in AH.
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